The U.S. Senate Committee on Appropriations has requested for the U.S. Federal Drug Administration (FDA) to allocate funds and resources toward the establishment of a regulatory framework for all cannabis derivatives, including cannabidiol (CBD). The “Cannabis and Cannabis Derivatives” section of the appropriations package states that within 90 days of enactment of the Act, the FDA shall issue a policy of enforcement discretion with regard to certain products containing CBD. In addition, the Committee requested that the FDA consider moving forward with research regarding CBD and encourages the agency to partner with academic institutions to expand sampling studies of CBD products on the market.